
Claims

1. A compound which is 17-chloro-5,13,14,22-tetramethyl-28-oxa-2,9-dithia-5,6,12,13,22-pentaazaheptacyclo[27.7.1.1^{4,7}.0^{11,15}.0^{16,21}.0^{20,24}.0^{30,35}]octatriaconta-1(37),4(38),6,11,14,16,18,20,23,29,31,33,35-tridecaene-23-carboxylic acid (Formula I)




(I)

or a pharmaceutically acceptable salt thereof.

2. The compound of claim 1.

3. The pharmaceutically acceptable salt of the compound of claim 1.

4. The compound of claim 1, wherein the compound of Formula I has the structure of (R_a)-17-chloro-5,13,14,22-tetramethyl-28-oxa-2,9-dithia-5,6,12,13,22-pentaazaheptacyclo[27.7.1.1^{4,7}.0^{11,15}.0^{16,21}.0^{20,24}.0^{30,35}]octatriaconta-1(37),4(38),6,11,14,16,18,20,23,29,31,33,35-tridecaene-23-carboxylic acid (Formula II)




(II)

or a pharmaceutically acceptable salt thereof.

5. The compound of claim 4.

6. The pharmaceutically acceptable salt of the compound of claim 4.

7. The compound of claim 1, wherein the compound of Formula I has the structure of (S_a)-17-chloro-5,13,14,22-tetramethyl-28-oxa-2,9-dithia-5,6,12,13,22-pentaazaheptacyclo[27.7.1.1^{4,7}.0^{11,15}.0^{16,21}.0^{20,24}.0^{30,35}]octatriaconta-1(37),4(38),6,11,14,16,18,20,23,29,31,33,35-tridecaene-23-carboxylic acid (Formula III)



(III)


or a pharmaceutically acceptable salt thereof.

8. The compound of claim 7.

9. The pharmaceutically acceptable salt of the compound of claim 7.

10. The compound, or pharmaceutically acceptable salt thereof, of any one of claims 1-9, in crystalline form.

11. A solid form of (R_a)-17-chloro-5,13,14,22-tetramethyl-28-oxa-2,9-dithia-5,6,12,13,22-pentaazaheptacyclo[27.7.1.1^{4,7}.0^{11,15}.0^{16,21}.0^{20,24}.0^{30,35}]octatriaconta-1(37),4(38),6,11,14,16,18,20,23,29,31,33,35-tridecaene-23-carboxylic acid (Formula II)



(II)

or a pharmaceutically acceptable salt thereof.

12. The solid form of claim 11, wherein the solid form is Form A (R_a)-17-chloro-5,13,14,22-tetramethyl-28-oxa-2,9-dithia-5,6,12,13,22-pentaazaheptacyclo[27.7.1.1^{4,7}.0^{11,15}.0^{16,21}.0^{20,24}.0^{30,35}]octatriaconta-1(37),4(38),6,11,14,16,18,20,23,29,31,33,35-tridecaene-23-carboxylic acid monohydrate having an XRPD pattern comprising at least one peak expressed as 2θ (±0.2º) selected from 5.4°, 7.0°, 8.4°, 10.7°, 12.5°, 13.1°, 14.4°, 15.1°, 15.6°, 17.1° and 18.2°.

13. The solid form of claim 12, wherein the solid form has an XRPD pattern comprising at least one peak expressed as 2θ (±0.2º) selected from 7.0°, 8.4° and 12.5°.

14. The solid form of claim 12, wherein the solid form has an XRPD pattern substantially similar to Figure 1.

15. The solid form of claim 12, wherein the solid form has a DSC thermogram comprising an endotherm with a desolvation onset at about 121 °C and a peak at about 152 °C.

16. The solid form of claim 12, wherein the solid form has a DSC thermogram comprising an endotherm with a melting/decomposition onset at about 181 °C and a peak at about 194 °C.

17. The solid form of claim 12, wherein the solid form has a DSC pattern substantially similar to Figure 2.

18. The solid form of claim 12, wherein the solid form has a TGA thermogram exhibiting a mass loss of about 4.0% upon heating from about 25 °C to about 160 °C.

19. The solid form of claim 12, wherein the solid form has a TGA pattern substantially similar to Figure 2.

20. A pharmaceutical composition comprising a compound of any one of claims 1-11, or a pharmaceutically acceptable salt thereof and a pharmaceutical excipient, carrier or diluent.

21. A compound of any one of claims 1-19, or a pharmaceutically acceptable salt thereof, for use in treating cancer.

22. The compound for use of claim 21, wherein the cancer is a hematological cancer or a solid tumor.

23. The compound for use of claim 22, wherein the hematological cancer is selected from acute myeloid leukemia, multiple myeloma, mantle cell lymphoma, chronic lymphocytic leukemia, diffuse large B cell lymphoma, Burkitt’s lymphoma and follicular lymphoma.

24. The compound of claim 22, wherein the solid tumor is selected from non-small cell lung cancer, small cell lung cancer, breast cancer, neuroblastoma, prostate cancer, melanoma, pancreatic cancer, uterine, endometrial cancer and colon cancer.